Anak, SemaYalman, NevinBilgen, HülyaSepet, ElifDeviren, AyhanGürtekin, BaşakTunca, FatihBaşaran, Bora2020-07-292020-07-292020Anak, S., Yalman, N., Bilgen, H., Sepet, E., Deviren, A., Gürtekin, B. ... Başaran, B. (2020). Squamous cell carcinoma development in Fanconi anemia patients who underwent hematopoietic stem cell transplantation. Pediatric Transplantation, 24(4). https://dx.doi.org/10.1111/petr.137061397-31421399-3046https://dx.doi.org/10.1111/petr.13706https://hdl.handle.net/20.500.12511/5640We examined SCC development of 24 FA patients, who received HSCT from HLA-matched relatives. In our BMT center, we applied low-dose CY + LFI + ATG (n:13) as conditioning regimen for FA patients between 1992 and 1999, and CY + BU + ATG (n:11) between 1999 and 2002. The aim of this study was to investigate SCC development after HSCT and examine features of the follow-up patients. The 10-year overall survival (OS) of the group with LFI + regimen was 43%, whereas the group without LFI regimen was 60%. There was a statistically significant relationship between infections (viral/bacterial) and overall survival (Fisher's Exact test P < .001). Five out of 13 long-term (>1 year) surviving patients developed SCC in the HNSCC (n:4) and esophagus (n:2) region (a patient with oral SCC developed a second primary esophageal SCC). The SCC rate in our FA patients was 38%, four of the SCC patients were transplanted with irradiation used conditioning regimens, three of them had acuteGvHD (Grade II-III), only one developed chronic GvHD. The interval between HSCT and SCC diagnosis was median 13 (range 6-18) years, the age for the development of cancer was median 21 (range 15-32) years. Survival after SCC was low, median 6 months (range 6-12), due to delayed SCC diagnosis, tumor progression under therapy and treatment-related toxicities of the usually reduced RT and/or CT.eninfo:eu-repo/semantics/embargoedAccessFanconi AnemiaGvHDHematopoietic Stem Cell TransplantationSquamous Cell CarcinomaArticle24410.1111/petr.13706Q4Q2